Drug evaluation: The C5a receptor antagonist PMX-53

Jörg Köhl*

*Corresponding author for this work
56 Citations (Scopus)


Peptech is developing PMX-53, a complement C5a inhibitor for the potential treatment of inflammatory disorders, including rheumatoid arthritis and psoriasis. Phase Ib/IIa clinical trials have been completed for both indications.

Original languageEnglish
JournalCurrent Opinion in Molecular Therapeutics
Issue number6
Pages (from-to)529-538
Number of pages10
Publication statusPublished - 01.12.2006


Dive into the research topics of 'Drug evaluation: The C5a receptor antagonist PMX-53'. Together they form a unique fingerprint.

Cite this